Literature DB >> 24384826

Occupational exposure in patients with the antisynthetase syndrome.

Ane Labirua-Iturburu1, Albert Selva-O'Callaghan, Jan-Paul Zock, Ramon Orriols, Xavier Martínez-Gómez, Miquel Vilardell-Tarrés.   

Abstract

Interstitial lung disease (ILD) is common in patients with myositis and is related with the presence of antisynthetase autoantibodies (aSA). Together with other manifestations, the resulting condition is known as the antisynthetase syndrome (ASS). Contact with certain environmental and occupational agents is also associated with the development of ILD. The objective of this study was to analyze occupational exposure and associated clinical manifestations in a cohort of patients with ASS. aSA had been identified by line immunoassay and confirmed by immunoprecipitation. Serial pulmonary function tests had been carried out to assess lung function. Thirty-two ASS patients and a control group of 32 myositis patients without aSA underwent a specific questionnaire interview to evaluate their cumulative exposure to biological dust, mineral dust, and gases/fumes up to disease onset. Comparisons were done with the Fisher exact test and Mann-Whitney test. Out from 32 ASS patients (median age, 42.7 yeras; IQR 32.2-52.5), twenty-six patients had anti-Jo-1, three anti-PL-12, and three anti-PL-7. Nine had polymyositis, 15 dermatomyositis, one amyopathic dermatomyositis, and seven pure ILD without myositis. Sixteen ASS patients (50 %) and seven (22 %) myositis patients without aSA had ever been highly exposed to dust, gases, or fumes (p < 0.05). A more than 10 % improvement in forced vital capacity occurred in 61 % of highly exposed patients and 23 % of those with low/no exposure (p = 0.06) over the observation period. In conclusion, a high percentage of patients with ASS had been exposed to dusts, gases, or fumes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24384826     DOI: 10.1007/s10067-013-2467-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  32 in total

1.  Lung function decline, chronic bronchitis, and occupational exposures in young adults.

Authors:  Jordi Sunyer; Jan Paul Zock; Hans Kromhout; Raquel Garcia-Esteban; Katja Radon; Deborah Jarvis; Kjell Toren; Nino Künzli; Dan Norbäck; Angelo d'Errico; Isabel Urrutia; Félix Payo; Mario Olivieri; Simona Villani; Marc Van Sprundel; Josep M Antó; Manolis Kogevinas
Journal:  Am J Respir Crit Care Med       Date:  2005-07-22       Impact factor: 21.405

2.  Spirometric reference values from a Mediterranean population.

Authors:  J Roca; J Sanchis; A Agusti-Vidal; F Segarra; D Navajas; R Rodriguez-Roisin; P Casan; S Sans
Journal:  Bull Eur Physiopathol Respir       Date:  1986 May-Jun

3.  Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.

Authors:  R Hubbard; S Lewis; K Richards; I Johnston; J Britton
Journal:  Lancet       Date:  1996-02-03       Impact factor: 79.321

4.  Outbreak of organising pneumonia in textile printing sprayers. Collaborative Group for the Study of Toxicity in Textile Aerographic Factories.

Authors:  C Moya; J M Antó; A J Taylor
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

5.  Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure.

Authors:  K Iwai; T Mori; N Yamada; M Yamaguchi; Y Hosoda
Journal:  Am J Respir Crit Care Med       Date:  1994-09       Impact factor: 21.405

Review 6.  Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?

Authors:  Geoffrey R Connors; Lisa Christopher-Stine; Chester V Oddis; Sonye K Danoff
Journal:  Chest       Date:  2010-12       Impact factor: 9.410

Review 7.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

8.  Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset.

Authors:  I Tillie-Leblond; M Wislez; D Valeyre; B Crestani; A Rabbat; D Israel-Biet; M Humbert; L J Couderc; B Wallaert; J Cadranel
Journal:  Thorax       Date:  2007-06-08       Impact factor: 9.139

9.  Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study.

Authors:  H Chinoy; S Adimulam; F Marriage; P New; M Vincze; E Zilahi; A Kapitány; A Gyetvai; L Ekholm; P Novota; M Remakova; P Charles; N J McHugh; L Padyukov; L Alfredsson; J Vencovsky; I E Lundberg; K Danko; W E Ollier; R G Cooper
Journal:  Ann Rheum Dis       Date:  2011-12-20       Impact factor: 19.103

Review 10.  Developments in the scientific and clinical understanding of inflammatory myopathies.

Authors:  Ingrid E Lundberg; Cecilia Grundtman
Journal:  Arthritis Res Ther       Date:  2008-10-10       Impact factor: 5.156

View more
  4 in total

Review 1.  [Antisynthetase syndromes].

Authors:  Jutta Bauhammer; Christoph Fiehn
Journal:  Z Rheumatol       Date:  2019-09       Impact factor: 1.372

2.  Environmental exposure in inflammatory myositis.

Authors:  A N Costa; L Kawano-Dourado; S K Shinjo; C R R Carvalho; R A Kairalla
Journal:  Clin Rheumatol       Date:  2014-03-21       Impact factor: 2.980

Review 3.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 4.  Environmental triggers of dermatomyositis: a narrative review.

Authors:  Christina E Bax; Spandana Maddukuri; Adarsh Ravishankar; Lisa Pappas-Taffer; Victoria P Werth
Journal:  Ann Transl Med       Date:  2021-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.